9月22日，瑞普生物盘中下跌2.00%，截至13:49，报21.51元/股，成交9734.56万元，换手率1.34%，总市 值99.97亿元。 资料显示，瑞普生物股份有限公司位于天津自贸试验区(空港经济区)东九道1号，成立日期2001年8月2 日，上市日期2010年9月17日，公司主营业务涉及兽用生物制品(动物疫苗)、化学药品、生物制剂、中 兽药及天然植物药物、预混合饲料及饲料添加剂、兽用原料药的研发、生产、销售及技术服务。主营业 务收入构成为：动保业务77.95%，宠物供应链22.05%。 瑞普生物所属申万行业为：农林牧渔-动物保健Ⅱ-动物保健Ⅲ。所属概念板块包括：禽流感药物、宠物 经济、原料药、合成生物、参股新三板等。 截至9月10日，瑞普生物股东户数2.60万，较上期增加0.00%；人均流通股12883股，较上期增加0.00%。 2025年1月-6月，瑞普生物实现营业收入17.08亿元，同比增长55.37%；归母净利润2.57亿元，同比增长 61.19%。 分红方面，瑞普生物A股上市后累计派现13.71亿元。近三年，累计派现4.62亿元。 资金流向方面，主力资金净流出402.84万元，特大单买入0.00 ...

Core Viewpoint - Reap Bio has shown a mixed performance in stock price, with a year-to-date increase of 20.43% but a recent decline of 2.11% over the last five trading days [2] Company Overview - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in Tianjin Free Trade Zone and specializes in veterinary biological products, chemical drugs, biological agents, and animal health products [2] - The company's main revenue sources are: poultry biological products (35.04%), formulations and raw materials (33.24%), pet supply chain (20.63%), livestock biological products (6.86%), and others [2] Financial Performance - For the first half of 2025, Reap Bio achieved a revenue of 1.708 billion yuan, representing a year-on-year growth of 55.37%, and a net profit attributable to shareholders of 257 million yuan, up 61.19% [2] - Since its A-share listing, the company has distributed a total of 1.371 billion yuan in dividends, with 462 million yuan in the last three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders stood at 27,000, with an average of 12,406 circulating shares per person [2] - Major shareholders include Hong Kong Central Clearing Limited and Guotai CSI Livestock Breeding ETF, with notable changes in their holdings [3]

Core Viewpoint - The stock of Reap Bio has experienced fluctuations, with a recent decline in price and significant trading activity, indicating potential investor concerns and market dynamics [1][2]. Company Overview - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in the Tianjin Free Trade Zone and specializes in veterinary biological products, chemical drugs, biological agents, and animal health products [2]. - The company's main revenue sources include poultry biological products (35.04%), formulations and raw materials (33.24%), pet supply chain (20.63%), livestock biological products (6.86%), and others [2]. Financial Performance - For the first half of 2025, Reap Bio reported a revenue of 1.708 billion yuan, representing a year-on-year growth of 55.37%, and a net profit attributable to shareholders of 257 million yuan, up 61.19% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 1.371 billion yuan in dividends, with 462 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited and Guotai CSI Livestock Breeding ETF, with notable changes in their holdings [3].

Company Overview - Reap Bio is located in Tianjin Free Trade Zone and was established on August 2, 2001, with its listing date on September 17, 2010 [1] - The company specializes in veterinary biological products (animal vaccines) and chemical pharmaceuticals [1] Stock Performance - As of August 22, Reap Bio's stock price decreased by 2.01%, trading at 22.93 CNY per share, with a total market capitalization of 10.657 billion CNY [1] - Year-to-date, the stock price has increased by 26.85%, with a 0.66% rise over the last five trading days, a 4.61% increase over the last 20 days, and a 7.02% decline over the last 60 days [1] Financial Performance - For the period from January to March 2025, Reap Bio reported a revenue of 822 million CNY, representing a year-on-year growth of 54.09% [2] - The company has distributed a total of 1.371 billion CNY in dividends since its A-share listing, with 462 million CNY distributed over the last three years [2] Shareholder Information - As of August 8, the number of shareholders for Reap Bio was 27,000, with an average of 12,406 circulating shares per shareholder [2] - As of March 31, 2025, the fifth largest circulating shareholder is Harvest Agricultural Industry Stock A, holding 6.3889 million shares, an increase of 696,900 shares from the previous period [2] Market Activity - On August 22, the net outflow of main funds was 7.9021 million CNY, with large orders accounting for 15.94% of purchases and 21% of sales [1]